Robert W. Baird Analysts Upgrade Alexion Pharmaceuticals Shares to "Outperform ... Web Inquirer ... development and commercialization of therapeutic products aimed at treating patients with severe and life-threatening disease states, including those in the therapeutic areas of hematology, nephrology (including transplant rejection), neurology, ... Alexion Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call Transcript |
